Table 1. Baseline characteristics and lipid medications at discharge for patients with follow-up lipid profile results.
| Characteristics | Value (n=484) | |
|---|---|---|
| Age (yr) | 62.7±10.5 | |
| Sex (male) | 387 (80.0) | |
| Indigenous | 90 (18.6) | |
| Dyslipidaemia history | 382 (78.9) | |
| Familial hypercholesterolaemia documented | 3 (0.6) | |
| Hypertension history | 360 (74.4) | |
| Diabetes history | 259 (53.5) | |
| Smoking history | 335 (69.2) | |
| Prior myocardial infarction | 303 (62.6) | |
| NSTEMI | 252 (52.1) | |
| STEMI | 51 (10.5) | |
| Body mass index (kg/m2) | 29.5±5.4 | |
| Surgery at age <60 years | 185 (38.2) | |
| Elective (non-urgent) surgery | 226 (46.7) | |
| Arterial graft used | 457 (94.4) | |
| Vein graft used | 431 (89.0) | |
| Concomitant valve or aortic procedure | 69 (14.3) | |
| Statin (any) | 469 (96.9) | |
| High-intensity | 425 (87.8) | |
| Moderate-intensity | 39 (8.1) | |
| Statin only | 387 (80.0) | |
| Ezetimibe only | 2 (0.4) | |
| Fibrate only | 1 (0.2) | |
| Statin plus ezetimibe | 57 (11.8) | |
| High-intensity statin plus ezetimibe | 46 (9.5) | |
| Statin plus fibrate | 24 (5.0) | |
| Statin plus ezetimibe plus fibrate | 1 (0.2) | |
| Ezetimibe plus fibrate | 1 (0.2) | |
| PCSK9 inhibitor plus ezetimibe | 1 (0.2)* | |
| No lipid-lowering medications | 10 (2.1) | |
Data are presented as mean±standard deviation or count (percent).
NSTEMI, non-ST-segment elevation myocardial infarction; PCSK9, proprotein convertase subtilisin-kexin type 9; STEMI, ST-segment elevation myocardial infarction.
*This patient was not prescribed a statin due to a history of statin intolerance.